Relying on previous findings that confirmed the association of low ALT with sarcopenia and frailty, we similarly ascertained in RCC patients that low ALT is a reliable biomarker for sarcopenia and frailty. The gene discussed is GPT; the disease is renal cell adenocarcinoma.